Stay updated with breaking news from Agenus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Agenus Inc. (NASDAQ:AGEN – Get Rating) has earned an average rating of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average twelve-month target price among brokerages that have […]
B. Riley reaffirmed their buy rating on shares of Agenus (NASDAQ:AGEN – Get Rating) in a research report sent to investors on Wednesday, Benzinga reports. They currently have a $8.00 target price on the biotechnology company’s stock. B. Riley also issued estimates for Agenus’ Q1 2023 earnings at ($0.20) EPS, Q2 2023 earnings at ($0.20) […]
B. Riley reiterated their buy rating on shares of Agenus (NASDAQ:AGEN – Get Rating) in a research report report published on Wednesday, Benzinga reports. B. Riley currently has a $8.00 price target on the biotechnology company’s stock. B. Riley also issued estimates for Agenus’ Q1 2023 earnings at ($0.20) EPS, Q2 2023 earnings at ($0.20) […]
Agenus Inc. , an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that its Board of Directors has declared a dividend of 5... | March 30, 2023
Item 8.01 Other Events. On March 29, 2023, the board of directors of Agenus Inc. declared a stock dividend consisting of an aggregate of 5,000,000 shares of common stock, par value... | March 30, 2023